Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Pancreatic Cancer
NCT06423326Phase 2Recruiting
- Sponsor
- Georgetown University
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, Cisplatin micelle injection (HA132), paclitaxel in pancreatic ductal adenocarcinoma (PDAC), sponsored by Georgetown University. Started Aug 2024; status: recruiting.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)paclitaxel
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06423326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06423326.